What Is The Flt3 Mutation And How Is It Treated?

The FLT3 mutation is a genetic change in bone marrow cells that can drive a fast-growing form of acute myeloid leukemia (AML). It is not a disease itself but a biomarker found in about 30% of AML cases. Treatment focuses on targeted drugs called FLT3 inhibitors, often combined with standard chemotherapy, and these have improved survival in recent years.

What Causes the FLT3 Mutation to Develop?

FLT3 stands for Fms-like tyrosine kinase 3. It is a gene that normally helps your body make healthy blood cells. When a mutation occurs, the gene gets stuck in the “on” position. This sends constant signals for cells to grow and multiply without stopping.

Researchers do not know exactly why FLT3 mutations happen. They are acquired mutations, meaning you are not born with them. They develop during your lifetime in a single bone marrow cell. There is no known link to lifestyle, diet, or environmental exposure that causes it directly.

Two main types of FLT3 mutations exist. The more common one is called FLT3-ITD (internal tandem duplication). The less common one is FLT3-TKD (tyrosine kinase domain). Both lead to uncontrolled cell growth but respond slightly differently to treatment.

How Is the FLT3 Mutation Diagnosed?

Diagnosis happens through a bone marrow biopsy or blood test. A pathologist looks for the specific genetic change in the DNA of your blood cells. The National Comprehensive Cancer Network (NCCN) recommends testing for FLT3 mutations in all newly diagnosed AML patients.

The test results come back as either FLT3-positive or FLT3-negative. If positive, the report will also say whether it is an ITD or TKD mutation. This information directly affects which treatment your doctor will recommend.

Doctors also measure something called the allelic ratio. This tells them what percentage of your leukemia cells carry the mutation. A high ratio generally means a more aggressive disease and may lead to different treatment decisions.

What Is the FLT3 Mutation and How Is It Treated?

Treatment for FLT3-positive AML has changed significantly in the last decade. The standard approach combines chemotherapy with a targeted drug called a FLT3 inhibitor. These drugs specifically block the signal from the mutated FLT3 protein, slowing or stopping cancer cell growth.

Midostaurin (Rydapt) was the first FLT3 inhibitor approved by the FDA in 2017. Research published in the New England Journal of Medicine showed that adding midostaurin to standard chemotherapy improved overall survival in patients with FLT3-mutated AML. It is now a standard first-line treatment.

Gilteritinib (Xospata) is another FLT3 inhibitor approved for relapsed or refractory AML. Studies have found it works well even in patients who no longer respond to other treatments. Quizartinib is also approved in some countries for FLT3-ITD mutations.

What Are the Side Effects of FLT3 Inhibitors?

FLT3 inhibitors are targeted drugs, not traditional chemotherapy. That means their side effect profile is different and often more manageable. But they are not without risks.

Common side effects include nausea, vomiting, diarrhea, and fatigue. Some patients experience mouth sores or skin rashes. Gilteritinib can cause a condition called differentiation syndrome, which requires immediate medical attention.

More serious but less common side effects include heart rhythm changes. Midostaurin can increase the risk of lung inflammation. Your care team will monitor you closely with blood tests and EKGs during treatment.

• Nausea and vomiting affect about 50% of patients
• Diarrhea occurs in roughly 30% of cases
• Heart rhythm changes require regular monitoring
• Differentiation syndrome is rare but serious with gilteritinib

Side effects vary by drug and by person. Some patients tolerate these drugs well with few issues. Others need dose adjustments or supportive medications to manage symptoms.

Does a Stem Cell Transplant Change the Outlook?

For many patients with FLT3-mutated AML, a stem cell transplant offers the best chance for long-term remission. The mutation is associated with a higher risk of relapse, so doctors often recommend transplant after achieving first remission.

Research from the Fred Hutchinson Cancer Research Center shows that patients who receive a transplant while in remission have better outcomes than those who do not. The transplant replaces the diseased bone marrow with healthy donor cells.

FLT3 inhibitors are sometimes used after transplant to prevent relapse. This is called maintenance therapy. Sorafenib, another type of FLT3 inhibitor, has shown benefit in this setting. Studies suggest it reduces the risk of relapse after transplant.

Not everyone is a candidate for transplant. Age, overall health, and donor availability all play a role. Your doctor will discuss whether transplant is right for you based on your specific situation.

What Is the Prognosis for FLT3-Positive AML?

The outlook has improved dramatically since FLT3 inhibitors became available. Before these drugs, FLT3-ITD mutations carried a poor prognosis with high relapse rates. Now, combination therapy has changed that.

Data from clinical trials show that adding midostaurin to chemotherapy improves five-year survival by about 20% compared to chemotherapy alone. For patients who achieve remission and receive a transplant, long-term survival rates are even higher.

Prognosis depends on several factors. The type of mutation matters — FLT3-TKD generally has a better outlook than FLT3-ITD. The allelic ratio also plays a role. Patients with a low ratio tend to do better than those with a high ratio.

Age and overall health remain important. Younger patients with fewer other health problems typically have better outcomes. But targeted therapies have helped older adults who cannot tolerate intensive chemotherapy as well.

Common Misconceptions About FLT3 Mutations

A common myth is that the FLT3 mutation is hereditary. It is not. You cannot pass it to your children, and having a family member with it does not increase your risk. It is an acquired mutation that develops in bone marrow cells.

Another misconception is that FLT3-positive AML is untreatable. This was partially true before 2017 but is no longer accurate. Targeted therapies have turned this into a treatable form of leukemia with improving outcomes.

Some people believe that natural remedies or supplements can treat FLT3 mutations. There is no clinical evidence that any supplement, diet, or alternative therapy targets the FLT3 mutation directly. These should never replace standard medical treatment.